Project proposals for developing an Adverse Outcome Pathways (AOP) can be sent to the OECD Secretariat using the submission of proposals form. Government representatives, academic experts, industry experts, non-governmental organisations, scientific societies, etc. can submit project proposals. The National co-ordinators of the Test Guidelines programme are also available for queries, and should be informed about proposals submitted. Project proposals are reviewed twice a year and included in the workplan if justified.
List of projects
|
Project 1.2: The Adverse Outcome Pathways for Partitioning of nonpolar narcotic compounds into cellular membranes leading to decreased physiological performance (formerly the AOP for Nonpolar Narcosis) |
|||
|
Lead: Inclusion in work plan: |
2012, update submitted in 2015 |
||
|
Project 1.6: The Adverse Outcome Pathways for Embryonic Vascular Disruption and Developmental Defects |
|||
|
Lead: Inclusion in work plan: |
2013 |
||
|
Project 1.11: The AOP for Heritable Germ Cell-Derived Disease |
|||
|
Lead: Inclusion in work plan: |
2013 AOP 1: Alkylation of DNA in male pre-meiotic germ cells causing inherited mutation - Completed AOP 2: Chemical interaction with tubulin in oocytes leading to inherited aneuploidy AOP 3: Stable bulky DNA adducts in male pre-meiotic germ cells causing point mutation leading to inherited DNA sequence mutation |
||
|
Project 1.12: The AOPs Linking Aromatase Inhibition, Androgen Receptor Agonism, Estrogen Receptor Antagonism, or Steroidogenesis Inhibition, to Impaired Reproduction in Small Repeat-Spawning Fish Species |
|||
|
Lead: Inclusion in work plan: |
2013 AOP 1: Adverse Outcome Pathway on Aromatase Inhibition Leading to Reproductive Dysfunction (in Fish) - Completed AOP 2: Androgen receptor agonism leadfing to reproductive dysfunction AOP 3: Estrogen receptor antagonism leading to reproductive dysfunction AOP 4: Estrogen receptor antagonism leading to reproductive dysfunction AOP 5: Androgen receptor antagonism leading to reproductive dysfunction |
||
|
Project 1.13: The AOPs on Neurotoxicant-induced Neuroinflammation: a converging key event in an adverse outcome pathway |
|||
|
Lead: Inclusion in work plan: |
2013 AOP1: Binding to SH/selen-proteins can trigger neuroinflammation leading to neurodegeneration AOP2: Binding of antagonists to NMDAR can trigger neuroinflammation leading to neurodegeneration |
||
|
Project 1.17: The AOP on CAR and PPARα-mediated pathways to non-genotoxic rodent liver cancer |
|||
|
Lead: Inclusion in work plan: |
2013 |
||
|
Project 1.19: The AOP from bile salt export pump inhibition to cholestatic liver injury |
|
|
Lead: Inclusion in work plan: |
2013 |
|
Project 1.20: The AOP for Sensitisation of the Respiratory Tract Induced by Covalent Binding to Proteins |
|
|
Lead: Inclusion in work plan: |
2013 |
|
Project 1.21: Three AOPs from peroxisome proliferator-activated receptors (PPARs) activation leading to reproductive toxicity in rodents |
|
|
Lead: Inclusion in work plan: |
2014 AOP1: PPAR alpha activation leading to decreased fertility upon utero exposure in rodent males AOP2: PPARγ activation leading to decreased fertility in adult female rodents AOP3: PPARα activation leading to decreased fertility in male rodents |
|
Project 1.24: The AOP from Cyp2E1 stabilization by substrate binding leading to liver cancer |
|
|
Lead: Inclusion in work plan: |
2014 |
|
Project 1.25: The AOP from Induction of Secretion of Inflammatory Cytokines Leading to Lung Emphysema |
|
|
Lead: Inclusion in work plan: |
2014 |
|
Project 1.32: The AOP From induction of secretion of inflammatory cytokines leading to lung fibrosis |
|
|
Lead: Inclusion in work plan: |
2015 |
|
Project 1.35: An AOP network for thyroid hormone system disruption in fish |
|
|
Lead: Inclusion in work plan: |
Belgium, Denmark, Germany, United States of America Updated in 2021 (Initially submitted in 2015 with the following title: The AOP on Thyroperoxidase and/or deiodinase inhibition leading to impaired swim bladder inflation in fish during early life stages). |
|
Project 1.36: The AOP on Cytotoxicity leading to nasal tumours |
|
|
Lead: Inclusion in work plan: |
2015 |
|
Project 1.38: The AOP on Binding of FK506-binding protein 12 (FKBP12) by calcineurin inhibitors leading to immunosuppression |
|||
|
Lead: Inclusion in work plan: |
2015 |
||
|
Project 1.39: The AOP on Phospholipase A inhibitors leading to hepatotoxicity |
|||
|
Lead: Inclusion in work plan: |
2015 |
||
| Project 1.40: The AOP for Kidney dysfunction by decreased thyroid hormone |
|||
|
Lead: Inclusion in work plan: |
Korea
2015 |
||
|
Project 1.41: The AOP on inhibition of thyroid hormone binding to transthyretin and subsequent adverse mammalian developmental neurotoxicity |
|||
|
Lead: Inclusion in work plan: |
ICAPO
2015 |
||
| Project 1.42: The Adverse Outcome Pathway on AhR / beta-catenin signalling leading to placental vascular disruption | |||
| Lead:
Inclusion in work plan: |
2015 |
||
| Project 1.43: The Adverse Outcome Pathway on AOP of proximal tubule injury mediated by covalent protein binding and lysosomal overload | |||
| Lead:
Inclusion in work plan: |
2016 |
||
| Project 1.44: The Adverse Outcome Pathway on Adverse Outcome Pathways for cranio-facial skeletal defects | |||
| Lead:
Inclusion in work plan: |
Italy, Sweden and the Netherlands 2016 |
||
| Project 1.45: The Adverse Outcome Pathway on Blocking of L-type Ca++ channels leading to heart failure | |||
| Lead:
Inclusion in work plan: |
UK and European Commission (JRC) 2016 |
||
| Project 1.47: The Adverse Outcome Pathway on Lysosomal damage leading to liver inflammation | |||
| Lead:
Inclusion in work plan: |
2016 |
||
| Project 1.48: The Adverse Outcome Pathway on Dysregulation of IL-2 transcription leading to immunotoxicity | |||
| Lead:
Inclusion in work plan: |
2016 |
||
| Project 1.49: The Adverse Outcome Pathway on ROS induces phototoxic reactions | |||
| Lead:
Inclusion in work plan: |
2016 |
||
|
Project 1.52: The Adverse Outcome Pathway on Histone deacetylase inhibition leading to testicular toxicity |
|||
|
Lead: Inclusion in work plan: |
2016 |
||
|
Project 1.53: The Adverse Outcome Pathway in utero DNA topoisomerase II inhibition leading to infant leukaemia |
|||
|
Lead: Inclusion in work plan: |
2016 |
||
|
Project 1.54: PPARγ inactivation leading to lung fibrosis |
|||
|
Lead: Inclusion in work plan:: |
2017 |
||
| Project 1.55: Secretion of inflammatory cytokines after cellular sensing of the stressor leading to plaque progression | |||
|
Lead: Inclusion in work plan: |
2017 |
||
| Project 1.56: DNA double strand breaks leading to lung cancer | |||
|
Lead: Inclusion in work plan: |
2017 |
||
| Project 1.58: Wnt ligand stimulation and Wnt signalling activation lead to cancer malignancy | |||
|
Lead: Inclusion in work plan: |
2019 |
||
| Project 1.59: TPO inhibition leading to impaired fertility in fish | |||
|
Lead: Inclusion in work plan: |
2019 |
||
| Project 1.60: Decreased Trypsin activity leading to pancreatic acinar cell tumour formation in rodents | |||
|
Lead: Inclusion in work plan: |
2019 |
||
| Project 1.61: Vitamin D3 receptor activation leading to adrenal pheochromocytoma formation in rats | |||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.62: Increased low-digestible carbohydrates in the colon leading to adrenal pheochromocytoma formation in rats |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.63: Sodium glucose cotransporter (SGLT1) inhibition leading to adrenal pheochromocytoma formation in rats |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.64: Inhibition of vesicular monoamine transporter (VMAT) leading to adrenal pheochromocytoma formation in rats |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.65: D2 receptor antagonism leading to pituitary tumour in mice |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.66: H/K-ATPase (proton pump) inhibition leading to gastric carcinoid tumour formation in rodents |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.67: Histamine receptor 2 blockade leading to gastric carcinoid tumour formation in rodents |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.68: : GLP-1 receptor activation leading to thyroid C-cell tumours in rodents |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.69: Alpha-glucosidase inhibition leading to renal tubular tumours in rats |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.70: Anti-dopaminergic activity leading to pancreatic islet cell tumour in rats |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.71: Increased low-digestible carbohydrates in the colon leading to Leydig cell tumour in rats |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.72: Dopamine agonism/ enhancement leading to Leydig cell tumour in rats |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.73:Activation of estrogen receptors in immune cells exacerbates allergic responses |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.74: Inhibition of JAK3 leading to impairment of TDAR |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.75: Activation of TLR 7 leading to psoriatic skin disease |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.76: Development of intersecting AOPs that address genetic toxicology endpoints by an expert community |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.77: Inhibition of retinaldehyde dehydrogenase leads to population decline |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.78: Inhibition of tyrosinase leads to decreased population of fish |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
| Project 1.79: Early-life stromal estrogen receptor activation by endocrine disrupting chemicals in the mammary gland leading to enhanced cancer risk | |||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.80: AOPS for RONS and DNA damage leading to increased risk of Breast Cancer |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
| Project 1.81: Inhibition of 5a-reductase leading to impaired fertility in female fish | |||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.82: Reduced binding of TH to THR in developing brain cells leads to mental retardation due to alteration in white matter |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.83: Disrupted laminin-beta1-integrin interaction leading to developmental neurotoxicity |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.84: Thyroid receptor antagonism leading to decreased cognitive function |
|||
|
Lead: Inclusion in work plan: |
USA, Germany, ICAPO 2019 |
||
|
Project 1.85: Oxidative Stress-Mediated Lung Fibrosis |
|||
|
Lead: Inclusion in work plan: |
2019 |
||
|
Project 1.86: Frustrated Phagocytosis-induced lung cancer |
|||
|
Lead: Inclusion in work plan: |
Institut National de Recherche et de Sécurité (INRS) - France 2019 |
||
|
Project 1.87: Lung Surfactant function disruption leading to acute lung toxicity |
|||
|
Lead: Inclusion in work plan: |
Denmark (The National Research Centre for the Working Environment) 2019 |
||
|
Project 1.88: Interactions with lung tissues leading to lung fibrosis via a pathway involving Trefoil Factor 2 |
|||
|
Lead: Inclusion in work plan: |
SmartNano Tox consortium (Finland, Germany, Ireland, Canada, Denmark) 2020 |
||
|
Project 1.89: The development of AOPs relevant to space flight health outcomes |
|||
|
Lead: Inclusion in work plan: |
2020 |
||
|
Project 1.90: Perturbed androgen signalling leads to short male anogenital distanceoject 1.83: Disrupted laminin-beta1-integrin interaction leading to developmental neurotoxicity |
|||
|
Lead: Inclusion in work plan: |
National Food Institute, Technical University of Denmark 2020 |
||
|
Project 1.91: Binding to voltage gate sodium channel leading to developmental neurotoxic effects (and acute neurotoxicity) |
|||
|
Lead: Inclusion in work plan: |
European food safety authority 2020 |
||
|
Project 1.92: The AOP for mitochondrial dysfunction in aquatic organisms |
|||
|
Lead: Inclusion in work plan: |
Norwegian Institute for Water Research (NIVA) 2021 |
||
|
Project 1.93: AOPs leading to decreased trajectory in fish population |
|||
|
Lead: Inclusion in work plan: |
2021 |
||
|
Project 1.94: Inhibition of Chitin Synthesis and Chitin Degradation in Arthropods |
|||
|
Lead: Inclusion in work plan: |
Norwegian Institute for Water Research 2021 |
||
|
Project 1.95: Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis |
|||
|
Lead: Inclusion in work plan: |
2021 |
||
|
Project 1.96: Submissions received under the CIAO related project (Modelling the pathogenesis of COVID-19 using the Adverse Outcome Pathway framework |
|||
|
Lead: Inclusion in work plan: |
European Commission (JRC), Humane Society International, Physicians Committee for Responsible Medicine 2021 |
||
|
Project 1.97:Inhibition of ALDH1A leads to decreased fertility, females |
|||
|
Lead: Inclusion in work plan: |
2021 |
||
|
Project 1.98:Development of an AOP for celiac disease |
|||
|
Lead: Inclusion in work plan: |
European food safety authority 2021 |
||
|
Project 1.99: Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity |
|||
|
Lead: Inclusion in work plan: |
2021 |
||
|
Project 1.100: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation |
|||
|
Lead: Inclusion in work plan: |
2022 |
||
|
Project 1.101: Disruption of the sonic hedgehog pathway during development leads to orofacial clefting |
|||
|
Lead: Inclusion in work plan: |
2022 |
||
|
Project 1.102: AOP network leading to heart failure and increase in mortality |
|||
|
Lead: Inclusion in work plan: |
2022 |
||
|
Project 1.103: DNA damage and mutations leading to Metastatic Breast Cancer |
|||
|
Lead: Inclusion in work plan: |
2022 |
||
|
Project 1.104: Hypothalamic estrogen receptors inhibition leading to ovarian cancer |
|||
|
Lead: Inclusion in work plan: |
2022 |
||
|
Project 1.105: Activation of the AhR leading to breast cancer |
|||
|
Lead: Inclusion in work plan: |
2022 |
||
|
Project 3.1: Development of a Template for Recording Adverse Outcome Pathways (AOPs) and Associated Guidance Relating to How to Assess its Completeness |
|
|
Lead: Inclusion in work plan: |
2011 Guidance and template published (No. 184 in OECD Series on Testing and Assessment) Currently under revision Users' Handbook released in September 2014, updated in 2018 Continuous feed back on the guidance/handbook documents and the wiki have been put in place. |
|
Project 4.4: Adverse Outcome Pathways Knowledge Base 2.0 (AOP-KB) |
|
|
Lead: Inclusion in work plan: |
European Commission, US EPA and Secretariat 2017 |
|
Project 5.3: Construction of a series of guidance documents for consistent reporting of ‘omics data from various sources |
|||
|
Lead: Inclusion in work plan: |
PHE and University of Birmingham (UoB) - UK/Health Canada/US EPA 2017 |
||
THE PROGRAMME
Related Documents